Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
74.10 USD | -1.12% | -0.98% | -13.69% |
Sep. 28 | GSK lifts growth ambitions for HIV business on long-acting drug | RE |
Sep. 19 | Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication | MT |
Evolution of the average Target Price on Gilead Sciences, Inc.
Price target over the last 5 years
History : Analyst Recommendations
6161e0041e1ae848b25de3d821cc9.fOTYg07zkd8o7uqDFIaGOixkDWu23cqiLHFGheSsb70.TtePyBSiqYl_nKmwV9zBa0EpXTiB747GYT0v9andKYgOvIfBNLmom36IiQ~08c9243633df637b16bf82e1fcd68547
More recommendations
Analysts' Consensus
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
74.10USD
Average target price
91.36USD
Spread / Average Target
+23.30%
High Price Target
116.00USD
Spread / Highest target
+56.55%
Low Price Target
71.00USD
Spread / Lowest Target
-4.18%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Gilead Sciences, Inc.
BofA Securities | |
HSBC | |
UBS | |
Goldman Sachs | |
Morgan Stanley | |
RBC Capital Markets | |
Piper Sandler | |
Barclays | |
Cantor Fitzgerald | |
BMO Capital | |
Mizuho Securities | |
SVB Securities LLC | |
Wells Fargo Securities | |
Oppenheimer | |
Cowen | |
Maxim | |
Truist Securities | |
JPMorgan Chase | |
Argus | |
SVB Leerink | |
Credit Suisse | |
Bernstein | |
Redburn | |
DZ BANK | Elmar Kraus |
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-